Navigation Links
Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clinical Trials
Date:5/14/2009

NATICK, Mass., May 14 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced data from its ALTITUDE Clinical Science program that show real-word survival rates for implantable cardiac device patients exceeding rates from clinical trials. ALTITUDE analyzes outcomes data from patients monitored by the LATITUDE(R) Patient Management system. Five-year survival rate data for patients using implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds) were presented at the Heart Rhythm Society Scientific Sessions in Boston by Leslie Saxon, M.D., F.A.C.C., Chief, Cardiovascular Medicine at the Cardiovascular and Thoracic Institute, University of Southern California, and chairperson of the ALTITUDE physician panel.

Boston Scientific has enrolled more than 130,000 patients on the LATITUDE system since its introduction in 2006, making it the most rapidly adopted remote cardiac device monitoring system in the industry(1). The LATITUDE system enables physicians to schedule remote follow-ups of implantable cardiac device patients to monitor specific device information and heart health status. The system can also detect clinical events between scheduled visits and send relevant data directly to physicians. This regular, in-home monitoring offers convenience and peace of mind for patients.

Findings presented today from ALTITUDE, which analyzed nearly 86,000 patients monitored by the LATITUDE system, include:

  • Five-year survival rates for ICD patients of up to 92 percent
  • Five-year survival rates for CRT-D patients of up to 78 percent

"In contrast to clinical trials, the ALTITUDE program analyzes device therapy in real-world practice and offers insights into clinical event rates and disease progression for extensive ICD and CRT-D patient populations," said Dr. Saxon. "This observational cohort study represents the largest cardiac device patient cohort to date and clearly shows survival rates exceed those reported in randomized trials."

"Boston Scientific is known for excellence in its clinical trials, such as MADIT, MADIT II, COMPANION and MADIT-CRT," said Fred Colen, President, Boston Scientific Cardiac Rhythm Management. "We're also proud of our significant investment in physician research through post-market analysis. The ALTITUDE Clinical Science program serves physicians by enhancing their understanding of device therapy, outcomes and disease progression in real-world device patients monitored by LATITUDE."

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, scientific activities, product performance, competitive offerings and growth investment. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

(1) Data based on number of patients at three years post-launch. Data on file.

    CONTACT:  David Knutson
              651-582-6574 (office)
              651-260-8288 (cell)
              Media Relations
              Boston Scientific Corporation

              Paul Donovan
              508-650-8541 (office)
              508-667-5165 (mobile)
              Media Relations
              Boston Scientific Corporation

              Larry Neumann
              508-650-8696 (office)
              Investor Relations
              Boston Scientific Corporation


'/>"/>
SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Journal of American College of Cardiology Article Reports Fewer Repeat Procedures With Boston Scientifics TAXUS(R) Liberte(R) Stent
2. Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine
3. Clinical Data Reinforce Safety and Efficacy of Boston Scientifics Two Drug- Eluting Stent Platforms
4. New England Journal of Medicine Publishes Results from Boston Scientifics Landmark SYNTAX(TM) Trial
5. Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents
6. Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent
7. Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientifics Next-Generation Taxus Liberte Stent
8. Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008
9. Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent
10. Wound Management Technologies, Inc. Announces Conference Plans in Boston and Additional Clinical Research on CellerateRx(R)
11. NIH Funds New Wellstone Research Center for Muscular Dystrophy at Boston Biomedical Research Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
Breaking Medicine Technology:
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
Breaking Medicine News(10 mins):